Skip to Content

Label Changes for:

Desferal (deferoxamine mesylate) injection

September 2010

Changes have been made to the WARNINGS and ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – September 2010




  • Increases in serum creatinine (possibly dose-related), acute renal failure and renal tubular

disorders, associated with the administration of deferoxamine, have been reported in

postmarketing experience


  • Hepatic: hepatic dysfunction

  • Urogenital: acute renal failure